JMP Securities Reiterates Market Outperform Rating on BioCryst Pharma (BCRX)

JMP Securities analyst Jonathan Wolleben reiterated a Market Outperform rating and $18.00 price target on BioCryst Pharma (NASDAQ: BCRX).

The analyst commented, “BCRX’s Orladeyo will be featured in multiple poster presentations throughout the conference largely focused on the drug’s real-world efficacy. We are interested in the interim data from the ongoing open-label APeX-P trial of berotralstat in children (2-<12 years) during Sunday’s (Mar. 2) late-breaking poster session showing a median monthly attack rate of 0 from months 1-12. BCRX remains on track to submit its sNDA for Orladeyo in pediatric HAE patients this year, which could increase the addressable population by ~500 patients.”

For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.

Shares of BioCryst Pharma closed at $9.05 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• AI/ML Innovations plans $2M private placement on the CSE
• Critical One Energy closes second tranche of flow-through placement